Trade Names:Declomycin- Tablets 150 mg- Tablets 300 mg
Inhibits bacterial protein synthesis.
Peak concentration is reached in about 4 h. The mean concentrations 1 and 3 h after 150 mg oral dose are 0.46 and 1.22 mcg/mL, respectively.
Penetrates well into various body fluids and tissues. Protein binding is about 40%.
Concentrated in the liver and excreted into the bile. Renal Cl is about 35 mL/min/1.73 m 2 . In data from a small number of patients, approximately 44% is excreted in the urine, and 13% to 46% is excreted in feces.
Treatment of infections caused by susceptible strains of gram-positive and gram-negative microorganisms.
Hypersensitivity to any tetracycline and any component of the product.
PO 150 mg 4 times daily or 300 mg twice daily.Children older than 8 yr of age
PO Usual dose is 7 to 13 mg/kg/day divided into 2 to 4 doses (max, 600 mg/day).GonorrheaAdults
PO 600 mg followed by 300 mg every 12 h for 4 days (total 3 g).
Store tablets at controlled room temperature (68° to 77°F).
May decrease the absorption of demeclocycline.Anticoagulants
Effect of anticoagulant may be enhanced, necessitating a downward adjustment in dosage.Methoxyflurane
Increased potential for life-threatening renal toxicity.Oral contraceptives
May reduce the effectiveness of oral contraceptives.Penicillins
The bactericidal action may be decreased by tetracyclines.
None well documented.
Pseudotumor cerebri; bulging fontanels (in infants); dizziness; headache; myasthenic syndrome.
Maculopapular and erythematous rashes; erythema multiforme; exfoliative dermatitis; fixed drug eruptions; Stevens-Johnson syndrome; pigmentation of skin and mucous membranes; lesions on the glans penis causing balanitis; phototoxicity.
Esophageal ulcerations; tinnitus; visual disturbances.
Anorexia; nausea; vomiting; diarrhea; glossitis; dysphagia; enterocolitis; pancreatitis; inflammatory lesions in the anogenital region (eg, monilial overgrowth); tooth discoloration (children younger than 8 yr of age).
Hemolytic anemia; thrombocytopenia; neutropenia; eosinophilia.
Increased liver enzymes; hepatic toxicity; hepatitis; liver failure.
Acute renal toxicity; increased BUN; nephrogenic diabetes insipidus.
Hypersensitivity (including urticaria, angioneurotic edema, polyarthralgia, anaphylaxis, anaphylactoid purpura, pericarditis, exacerbation of SLE, lupus-like syndrome, pulmonary infiltrates with eosinophilia); brown-black thyroid gland discoloration.
Ensure that CBC, liver enzymes, and renal function are periodically evaluated during prolonged therapy.
Category D .
Excreted in breast milk.
Safety and efficacy not established in children younger than 8 yr of age because abnormal bone formation and discoloration of teeth may occur.
May lead to excessive accumulation of the drug and possible liver toxicity; dosage reduction may be required.
Patients experiencing CNS symptoms should be cautioned about driving vehicles or using dangerous machinery.
Prolonged use may result in bacterial or fungal overgrowth.
May manifest as exaggerated sunburn.
Has been reported.
Copyright © 2009 Wolters Kluwer Health.